ORAMED PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.0M | — | $1.3M | $2.7M | $2.7M | $2.7M | $2.7M |
| Cost of Revenue | — | $2.0M | — | — | — | — | — | $90.0K |
| Gross Profit | — | $13.0K | — | — | — | — | — | $2.6M |
| Gross Margin | — | 0.7% | — | — | — | — | — | 96.7% |
| Operating Expenses | ||||||||
| Research & Development | — | $6.4M | $6.3M | $9.0M | $27.6M | $21.0M | $10.2M | $13.5M |
| SG&A Expense | — | $8.7M | $6.5M | $8.4M | $13.8M | $5.9M | $4.2M | $3.7M |
| Operating Income | — | $-15.1M | $-12.8M | $-15.8M | $-40.6M | $-24.2M | $-11.8M | $-14.6M |
| Operating Margin | — | -754.4% | — | -1,176.8% | -1,502.0% | -896.2% | -433.8% | -541.3% |
| Interest Expense | — | — | $2.6M | $2.0M | — | — | — | — |
| Pretax Income | — | $75.3M | $-15.9M | $5.1M | $-37.7M | — | $-11.5M | $-14.1M |
| Income Tax Expense | — | $11.3M | $3.2M | — | $100.0K | — | — | $300.0K |
| Net Income | — | $64.1M | $-19.1M | $5.1M | $-36.6M | $-23.0M | $-11.5M | $-14.4M |
| Net Margin | — | 3,202.5% | — | 379.7% | -1,352.6% | -850.5% | -424.8% | -531.1% |
| EPS (Basic) | — | $1.53 | $-0.48 | $0.14 | $-0.94 | $0.78 | $0.56 | $0.82 |
| EPS (Diluted) | — | $1.50 | $-0.48 | $0.14 | $-0.94 | $0.78 | $0.56 | $0.82 |
| Shares Outstanding (Basic) | 40.4M | 41.4M | 40.9M | 40.3M | 39.0M | 38.2M | 23.7M | 17.4M |
| Shares Outstanding (Diluted) | 40.4M | 42.4M | 40.9M | 40.6M | 39.0M | 38.2M | 23.7M | 17.4M |
| Dividends Per Share | — | $0.25 | — | — | — | — | — | — |